Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1831-1843

  Alkhalidi, Bashar A ^a   Tamimi, Jaafar J ^b   Salem, Isam I ^b   Ibrahim, Husain ^b   Sallam, Alsayed Alarabi I ^c  

^a UNIVERSITY OF JORDAN   (Jordan)

^b Arab Company for Drug Industries & Medical Appliances   (Jordan)

^c Research and Development Division   (Jordan)

Author keywords

bioequivalence; clarithromycin; extended release; HPLC; pharmacokinetics

Indexed keywords

CLARITHROMYCIN; KLACID XL; KLARIBAC XL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGE; ARAB; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY HEIGHT; BODY WEIGHT; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG SOLUBILITY; DRUG TOLERABILITY; ELECTROCHEMICAL DETECTION; EXTENDED RELEASE FORMULATION; FOOD; FOOD DRUG INTERACTION; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; JORDANIAN; MALE; MAXILLA SINUSITIS; MAXIMUM PLASMA CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CLARITHROMYCIN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FASTING; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; JORDAN; MALE; METABOLIC CLEARANCE RATE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 56149101713     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.010     Document Type: Article

References (32)

1. Morimoto S., Takahashi Y., Watanabe Y., and Omura S. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo) 37 (1984) 187-189
2. Neu H.C. The development of macrolides: Clarithromycin in perspective. J Antimicrob Chemother 27 Suppl A (1991) 1-9
3. Olsson-Liljequist B., and Hoffman B.M. In-vitro activity of clarithromycin combined with its 14-hydoxy metabolite A-62671 against Haemophilus influenzae. J Antimicrob Chemother 27 Suppl A (1991) 11-17
4. Chu S.Y., Deaton R., and Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 36 (1992) 1147-1150
5. Davey P.G. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 19 Suppl A (1991) 29-37
6. Fraschini F., Scaglione F., and Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 25 (1993) 189-204
7. Suwa T., Yoshida H., Fukushima K., and Nagate T. Metabolic fate of TE-031 A-56268 III. Absorption, distribution and excretion of 14C-TE-031 in rats, mice and dogs. Chemotherapy 36 (1988) 213-226
8. Biaxin XL [package insert] (2007), Abbott Laboratories, North Chicago, Ill
9. Guay D.R., Gustavson L.E., Devcich K.J., et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 23 (2001) 566-577
10. Gaete L.G., Schatloff O.B., Anziani F.O., et al. Bioequivalence of two formulations of modified-release clarithromycin available in the Chilean market [in Spanish]. Rev Chil Infectol 20 (2003) 171-177
11. Ishii K., Saito Y., Itai S., et al. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm 24 (1998) 129-137
12. Chu S., Park Y., Locke C., et al. Drugfood interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 32 (1992) 32-36
13. Cheng K.L., Nafziger A.N., Peloquin C.A., and Amsden G.W. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 42 (1998) 927-929
14. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 (September 17, 2008). http://www.wma.net/e/policy/b3.htm Accessed
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) (August 1, 2008). http://www.ich.org/MediaServer.jser?@_ID=482&@_MODE=GLB Accessed
16. The United States Pharmacopeia and National Formulary-Usp 26 Nf 21 (2003), US Pharmacopoeial Convention, Rockville, Md
17. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Dissolution testing of immediate release solid dosage forms. August 1997 (September 17, 2008). http://www.fda.gov/cder/Guidance/1713bp1.pdf Accessed
18. Hedenmo M., and Eriksson B.M. Liquid chromatographic determination of the macrolide antibiotics roxithromycin and clarithromycin in plasma by automated solid-phase extraction and electrochemical detection. J Chromatogr A 692 (1995) 161-166
19. Taninaka C., Ohtani H., Hanada E., et al. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high performance liquid chromatography with amperometric detection. J Chromatogr B Biomed Sci Appl 738 (2000) 405-411
20. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Bioanalytical method validation. May 2001 (September 17, 2008). http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm Accessed
21. Hirsch A.F. Good Laboratory Practice Regulations (1989), Marcel Dekker, New York, NY
22. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed (1982), Informa HealthCare USA, Inc, New York, NY
23. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987) 657-680
24. Ritschel W.A. Handbook of Basic Pharmacokinetics...including Clinical Applications. 4th ed (1992), Drug Intelligence Publications, Hamilton, Ill
25. Rowland M., and Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed (1995), Williams & Wilkins, Philadelphia, Pa
26. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed (1997), Marcel Dekker, New York, NY
27. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Statistical approaches to establishing bioequivalence. January 2001 (September 17, 2008). http://www.fda.gov/Cder/guidance/3616fnl.htm . Accessed
28. Chow S.C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY
29. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Revision 1. March 2003 (September 17, 2008). http://www.fda.gov/cder/guidance/5356fnl.htm Accessed
30. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies: Study design, data analysis, and labeling. December 2002 (September 17, 2008). http://www.fda.gov/CDER/guidance/5194fnl.htm Accessed
31. World Health Organization. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability (October 3, 2008). http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_0 93Rev4_final.pdf Accessed
32. Center for Drug Evaluation and Research, US Food and Drug Administration. Draft guidance on clarithromycin (October 3, 2008). http://www.fda.gov/October20081843B.A.Alkhalidietal.cder/guidance/bioequ ivalence/recommendations/Clarithromycin_ERtab_50775_RC1-08.pdf Accessed